Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma

Author(s):
Reijers, I.L.M.; Rozeman, E.A.; Mallo, H.; Uyterlinde, W.; Adriaansz, S.; Lijnsvelt, J.; Wilgenhof, S.; Thienen, J.V. van; Haanen, J.B.A.G.; Blank, C.U.
Published
2018
Publication type
Article / Letter to editor
Date issued
2018-10-31
Language
English
Is part of
Annals of Oncology (2018), Vol. 29, p. 449-449
hdl
1887/3627640